Dimensional Fund Advisors LP Boosts Holdings in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Dimensional Fund Advisors LP raised its holdings in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 128.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 166,590 shares of the company’s stock after purchasing an additional 93,511 shares during the period. Dimensional Fund Advisors LP’s holdings in Sensus Healthcare were worth $888,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Creekmur Asset Management LLC purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth about $83,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Sensus Healthcare during the first quarter worth about $155,000. Chapin Davis Inc. purchased a new stake in shares of Sensus Healthcare during the second quarter worth about $53,000. Acadian Asset Management LLC grew its holdings in shares of Sensus Healthcare by 578.6% during the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after buying an additional 38,474 shares in the last quarter. Finally, Sachetta LLC grew its holdings in shares of Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company’s stock worth $631,000 after buying an additional 13,544 shares in the last quarter. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Stock Performance

SRTS opened at $6.62 on Monday. The company’s 50 day simple moving average is $6.20 and its 200 day simple moving average is $5.39. Sensus Healthcare, Inc. has a 1 year low of $1.79 and a 1 year high of $7.18. The stock has a market capitalization of $108.52 million, a PE ratio of 22.83 and a beta of 1.05.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.07. Sensus Healthcare had a net margin of 18.27% and a return on equity of 13.46%. The business had revenue of $9.24 million for the quarter, compared to analysts’ expectations of $7.00 million. During the same period last year, the company earned ($0.02) earnings per share. As a group, sell-side analysts expect that Sensus Healthcare, Inc. will post 0.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SRTS. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sensus Healthcare in a report on Monday, August 12th. Roth Capital upgraded shares of Sensus Healthcare to a “strong-buy” rating in a report on Friday, July 12th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.